Cargando…
S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study
OBJECTIVE: Adrenocortical carcinoma (ACC) has an aggressive but variable clinical course. Prognostic stratification based on the European Network for the Study of Adrenal Tumours stage and Ki67 index is limited. We aimed to demonstrate the prognostic role of a points-based score (S-GRAS) in a large...
Autores principales: | Elhassan, Y S, Altieri, B, Berhane, S, Cosentini, D, Calabrese, A, Haissaguerre, M, Kastelan, D, Fragoso, M C B V, Bertherat, J, Al Ghuzlan, A, Haak, H, Boudina, M, Canu, L, Loli, P, Sherlock, M, Kimpel, O, Laganà, M, Sitch, A J, Kroiss, M, Arlt, W, Terzolo, M, Berruti, A, Deeks, J J, Libé, R, Fassnacht, M, Ronchi, C L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679848/ https://www.ncbi.nlm.nih.gov/pubmed/34709200 http://dx.doi.org/10.1530/EJE-21-0510 |
Ejemplares similares
-
Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study
por: Elhassan, Yasir, et al.
Publicado: (2021) -
Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study
por: Altieri, Barbara, et al.
Publicado: (2020) -
Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021) -
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
por: Terzolo, Massimo, et al.
Publicado: (2023) -
THU617 Prolonged Exposure To Target Mitotane Concentrations Is Associated With Better Recurrence-free Survival In Patients With Adrenocortical Carcinoma On Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2023)